A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema | NCT01918371 | Trialant
CompletedObservationalUpdated Apr 18, 2019
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
ClinicalTrials.gov ID
NCT01918371
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
323Actual
Last Update Posted
Apr 18, 2019Actual
Start Date
Aug 2, 2013Actual
Primary Completion Date
Sep 4, 2014Actual
Completion Date
Sep 4, 2014Actual
Brief Summary
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
Retinal Vein Occlusion
Macular Edema
Anti-VEGF
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
Macular edema in the study eye due to RVO or DME
Received an anti-VEGF injection in the study eye on or after June 2010 for RVO and on or after August 2012 for DME